Dr. Hu on Active Surveillance for Prostate Cancer

Jim Hu, MD, MPH
Published: Thursday, Sep 07, 2017



Jim Hu, MD, MPH, director of the LeFrak Center for Robotic Surgery at Weill Cornell Medicine/NewYork-Presbyterian Hospital and the Ronald Lynch Chair of Urologic Oncology at Weill Cornell Medical College, discusses active surveillance for patients with prostate cancer.

With the increased utilization of active surveillance, patients with prostate cancer are less likely to be overdiagnosed and overtreated. The health literacy of the patient and their family on the risks and benefits of screening will lead to a better individualized choice.



Jim Hu, MD, MPH, director of the LeFrak Center for Robotic Surgery at Weill Cornell Medicine/NewYork-Presbyterian Hospital and the Ronald Lynch Chair of Urologic Oncology at Weill Cornell Medical College, discusses active surveillance for patients with prostate cancer.

With the increased utilization of active surveillance, patients with prostate cancer are less likely to be overdiagnosed and overtreated. The health literacy of the patient and their family on the risks and benefits of screening will lead to a better individualized choice.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual International Congress of Oncology Pathology™: Towards Harmonization of Pathology and Oncology StandardsAug 30, 20182.0
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x